Breaking News

CordenPharma Strengthens xRNA-based Capabilities

Makes €10 million investment in LNP formulation services at its Caponago injectable facility.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

CordenPharma, a full-service contract development and manufacturing organization (CDMO) of active pharmaceutical ingredients (APIs), excipients, drug products and packaging services, has increased its xRNA capabilities at its sterile injectable facility in Caponago, Italy. The company reports that it is investing over €10 million in new Lipid Nanoparticle (LNP) formulation, development and production areas. The expansion will support customers to progress from pre-clinical and clinical dev...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters